Navigation überspringen
Universitätsbibliothek Heidelberg
Status: Bibliographieeintrag

Verfügbarkeit
Standort: ---
Exemplare: ---
heiBIB
 Online-Ressource
Verfasst von:Potthoff, Karin [VerfasserIn]   i
 Hofheinz, Ralf-Dieter [VerfasserIn]   i
 Hassel, Jessica C. [VerfasserIn]   i
 Volkenandt, M. [VerfasserIn]   i
 Lordick, F. [VerfasserIn]   i
 Hartmann, J. T. [VerfasserIn]   i
 Karthaus, M. [VerfasserIn]   i
 Riess, H. [VerfasserIn]   i
 Lipp, H. P. [VerfasserIn]   i
 Hauschild, A. [VerfasserIn]   i
 Trarbach, T. [VerfasserIn]   i
 Wollenberg, A. [VerfasserIn]   i
Titel:Interdisciplinary management of EGFR-inhibitor-induced skin reactions
Titelzusatz:a German expert opinion
Verf.angabe:K. Potthoff, R. Hofheinz, J.C. Hassel, M. Volkenandt, F. Lordick, J.T. Hartmann, M. Karthaus, H. Riess, H.P. Lipp, A. Hauschild, T. Trarbach, A. Wollenberg
Jahr:2011
Umfang:12 S.
Fussnoten:Available online 6 January 2020 ; Gesehen am 13.01.2023
Titel Quelle:Enthalten in: Annals of oncology
Ort Quelle:Amsterdam [u.a.] : Elsevier, 1990
Jahr Quelle:2011
Band/Heft Quelle:22(2011), 3, Seite 524-535
ISSN Quelle:1569-8041
Abstract:BACKGROUND: Anti-epidermal growth factor receptor treatment strategies, i.e. monoclonal antibodies such as cetuximab and panitumumab, or epidermal growth factor receptor (EGFR) small molecule tyrosine kinase inhibitors, such as erlotinib and gefitinib, have expanded the treatment options for different tumor types. Dermatologic toxic effects are the most common side-effects of EGFR inhibitor therapy. They can profoundly affect the patient's quality of life. - PURPOSE: The aim of this study was to provide interdisciplinary expert recommendations on how to treat patients with skin reactions undergoing anti-EGFR treatment. - MATERIAL AND METHODS: An expert panel from Germany with expertise in medical oncology, dermatology or clinical pharmacology was convened to develop expert recommendations based on published peer-reviewed literature. - RESULTS: The expert recommendations for the state-of-the-art treatment of skin reactions induced by EGFR inhibitor therapy include recommendations for diagnostics and grading as well as grade-specific and stage-adapted treatment approaches and preventive measures. It was concluded that EGFR-inhibitor-related dermatologic reactions should always be treated combining basic care of the skin and a specific therapy adapted to stage and grade of skin reaction. For grade 2 and above, specific treatment recommendations for early- and later-stage skin reactions induced by EGFR-inhibitor therapy were proposed. - CONCLUSION: This paper presents a German national expert opinion for the treatment of skin reactions in patients receiving EGFR inhibitor therapy.
DOI:doi:10.1093/annonc/mdq387
URL:Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.

Volltext: https://doi.org/10.1093/annonc/mdq387
 DOI: https://doi.org/10.1093/annonc/mdq387
Datenträger:Online-Ressource
Sprache:eng
Sach-SW:Acneiform Eruptions
 Antibodies, Monoclonal
 Antibodies, Monoclonal, Humanized
 Cetuximab
 Disease Management
 ErbB Receptors
 Germany
 Humans
 Panitumumab
 Vitamin K 3
K10plus-PPN:1831065835
Verknüpfungen:→ Zeitschrift

Permanenter Link auf diesen Titel (bookmarkfähig):  https://katalog.ub.uni-heidelberg.de/titel/69005928   QR-Code
zum Seitenanfang